Manandhar Preeti, Murnion Bridin Patricia, Grimsey Natasha L, Connor Mark, Santiago Marina
Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.
Drug and Alcohol Services, Central Coast Local Health District, Hamlyn Terrace, NSW, Australia.
PeerJ. 2021 Apr 12;9:e11175. doi: 10.7717/peerj.11175. eCollection 2021.
Pregabalin and gabapentin improve neuropathic pain symptoms but there are emerging concerns regarding their misuse. This is more pronounced among patients with substance use disorder, particularly involving opioids. Co-ingestion of gabapentinoids with opioids is increasingly identified in opioid related deaths, however, the molecular mechanism behind this is still unclear. We have sought to determine whether pregabalin or gabapentin directly modulates acute μ receptor signaling, or μ receptor activation by morphine.
The effects of pregabalin and gabapentin were assessed in HEK 293 cells stably transfected with the human μ receptor. Their effect on morphine induced hyperpolarization, cAMP production and ERK phosphorylation were studied using fluorescent-based membrane potential assay, bioluminescence based CAMYEL assay and ELISA assay, respectively. Pregabalin/gabapentin effects on morphine-induced hyperpolarization were also investigated in AtT20 cells.
Pregabalin or gabapentin (1 µM, 100 µM each) did not activate the µ receptor or affect K channel activation or ERK phosphorylation produced by morphine. Neither drug affected the desensitization of K channel activation produced by prolonged (30 min) application of morphine. Gabapentin (1 µM, 100 µM) and pregabalin (1 µM) did not affect inhibition of forskolin-stimulated cAMP production by morphine. However, pregabalin (100 µM) potentiated forskolin mediated cAMP production, although morphine still inhibited cAMP levels with a similar potency to control.
Pregabalin or gabapentin did not activate or modulate µ receptor signaling in three different assays. Our data do not support the hypothesis that gabapentin or pregabalin augment opioid effects through direct or allosteric modulation of the µ receptor. Pregabalin at a high concentration increases cAMP production independent of morphine. The mechanism of enhanced opioid-related harms from co-ingestion of pregabalin or gabapentin with opioids needs further investigation.
普瑞巴林和加巴喷丁可改善神经性疼痛症状,但人们对其滥用问题的担忧日益增加。这在物质使用障碍患者中更为明显,尤其是涉及阿片类药物的患者。在与阿片类药物相关的死亡中,越来越多地发现加巴喷丁类药物与阿片类药物同时摄入,然而,其背后的分子机制仍不清楚。我们试图确定普瑞巴林或加巴喷丁是否直接调节急性μ受体信号传导,或吗啡对μ受体的激活作用。
在稳定转染人μ受体的HEK 293细胞中评估普瑞巴林和加巴喷丁的作用。分别使用基于荧光的膜电位测定法、基于生物发光的CAMYEL测定法和ELISA测定法研究它们对吗啡诱导的超极化、cAMP产生和ERK磷酸化的影响。还在AtT20细胞中研究了普瑞巴林/加巴喷丁对吗啡诱导的超极化的影响。
普瑞巴林或加巴喷丁(各1μM、100μM)均未激活μ受体,也未影响吗啡产生的钾通道激活或ERK磷酸化。两种药物均未影响长时间(30分钟)应用吗啡所产生的钾通道激活的脱敏作用。加巴喷丁(1μM、100μM)和普瑞巴林(1μM)均未影响吗啡对福司可林刺激的cAMP产生的抑制作用。然而,普瑞巴林(100μM)增强了福司可林介导的cAMP产生,尽管吗啡仍以与对照相似的效力抑制cAMP水平。
在三种不同的测定中,普瑞巴林或加巴喷丁均未激活或调节μ受体信号传导。我们的数据不支持加巴喷丁或普瑞巴林通过对μ受体的直接或变构调节来增强阿片类药物作用的假设。高浓度的普瑞巴林可独立于吗啡增加cAMP的产生。普瑞巴林或加巴喷丁与阿片类药物同时摄入导致阿片类药物相关危害增加的机制需要进一步研究。